Long-term vascular-targeted therapies in high doses usually give rise to tumor hypoxia, and meanwhile, some specific cancer types are susceptible to anti-VEGF treatments, which underscores the importance of selecting appropriate doses and time ranges of anti-angiogenic drugs’ administration to achieve vascular normalization as initially expected, termed as “normalization window” [394, 395]. This evidence concerns the gene VEGFA and neoplasm.